Primary Perspective

Achieving Euglycemic Levels and Minimizing the Impact of Dysmetabolic Risk Factors in Diabetes Management: A Primary Perspective

Your certificate for continuing education credit (if applicable) will be issued from the following information.

Fields marked with an asterisk (*) are required.

Prefix:

Prefix (other):

*First Name: MI: *Last Name: *Degree(s):

Degree (add'l):

Title: *Specialty:

Specialty (other):

*Affiliation: *Practice Type:

Type (other):

Department: Years in Practice: x

Address:

Business Personal

Address Name:

*Address 1: Address 2: *City: *State:

*ZIP: *E-mail: *Day Phone: Ext.: Cell: Fax: x

What is the best time to contact you?

Because you have attended or shown interest in our programs, we may send you information on this and similar programs utilizing the e-mail address provided. You may unsubscribe at any time by clicking on the “unsubscribe” link on any e-mails sent from us.

Please do not send me information via e-mail.

We value the confidentiality of the information you choose to share with us and are committed to its protection. All personal information you provide is stored in a secure location and will never be sold or distributed to any third party.

EVALUATION

To enable us to maintain the highest scientific and educational standards when planning future activities, we would
appreciate your evaluation of this activity and its content.

PRESENTATIONS AND INTERACTIVE DISCUSSION	Excellent			Poor
	5	4	3	2	1
*Therapeutic Targets of Cardiometabolic Risk Management* Frank Svec, MD, PhD
Overall presentation
Clinical relevance
Presentation style/visuals
Successful Management Outcomes in Type 2 Diabetes: From Steps to Strategies Steven Haffner, MD
Overall presentation
Clinical relevance
Presentation style/visuals
*Diabetes Interventions: Advances in Therapeutic Agents* Catherine L. Martin, MS, APRN, BC-ADM, CDE
Overall presentation
Clinical relevance
Presentation style/visuals
Upon completion of this activity, I am better able to:	Agree			Disagree
	5	4	3	2	1
Explain role of PCCs as the first line of care in successful treatment and follow-up of patients with type 2 diabetes and dysmetabolic risk factors
Recognize the causal pathophysiologic relationship between pre-diabetes syndrome (β-cell dysfunction, insulin resistance, and IGT) and resultant type 2 diabetes
List the comorbid conditions and dysmetabolic risk factors related to the presence of IGT and type 2 diabetes (eg, obesity, dyslipidemia, hypertension, hyperinsulinemia, and elevated adipocytokine and inflammatory biomarker levels)
Compare peer-reviewed, consensus treatment guidelines for comorbid cardiovascular conditions associated with type 2 diabetes to determine appropriate treatment
Discuss the mechanisms, sites of action, and clinical benefits of IMs for the treatment of type 2 diabetes, as they relate to insulin and glucagon secretion, gastric emptying, satiety induction and resultant weight loss, and cardiovascular risk reduction
Review the clinical data for diabetes treatments—monotherapies and combination therapies—that achieve glucose homeostasis and confer pleiotropic benefits with mild, transient, and manageable adverse events
This activity:
Met my expectations
Was relevant to my clinical practice
Was presented without commercial bias
After participating in this activity, I will change my clinical practice by:

Additional comments:

POSTTEST

Please select the best answers to the posttest questions below.
1. What is the major risk factor for type 2 diabetes?
	Increased blood pressure
	Dyslipidemia
	Impaired blood glucose
	Obesity
	Microalbuminuria
2. What is the leading cause of diabetes-related deaths?
	Chronic kidney disease
	CVD
	Peripheral artery disease
	Impaired glucose tolerance
	Transient ischemic attack
3. In addition to endogenous insulin levels, what else progressively declines from prediabetes to diabetes?
	Postprandial plasma glucose
	Insulin resistance
	β-cell function
	Fasting blood glucose
	None of the above
4. What hormone is not involved in glucose homeostasis?
	Insulin
	GLP-1
	Glucagon
	Amylin
	Leptin
5. Which antidiabetes agents or classes slow gastric emptying and decrease food intake?
	Sitagliptin, metformin
	Exenatide, pramlintide
	Sulfonylurea, insulin
	Thiazolidinedione, α-glucosidase inhibitor
	Metformin, meglitinide
6. Weight loss may improve which of the following CVD risk factor parameters?
	A1C
	Blood pressure
	Lipids
	Inflammatory biomarkers
	All of the above
7. Which is not true about GLP-1?
	Decreases glucagon secretion
	Effects are diminished in patients with type 2 diabetes
	Decreases insulin secretion
	Actions are receptor-mediated
	Responsible for most of incretin effect
8. Which class of antidiabetes agents inhibits the degradation of endogenous GLP-1?
	DPP-IV inhibitor
	Biguanide
	Thiazolidinedione
	α-glucosidase inhibitor
	Sulfonylurea
9. Which of the following agents has been associated with the greatest weight loss?
	Metformin
	Exenatide
	Sitagliptin
	Thiazolidinedione
	None of the above
10. People at risk for type 2 diabetes should:
	Increase physical activity
	Lose 5% to 10% of body weight
	Quit smoking
	Obtain medical nutrition therapy guidance
	All of the above

This activity is supported by an independent educational grant provided by